AREC.LSE Arecor Therapeutics PLC
- Market cap
- GBX 37.4M
- P/E
- 82.5x
- P/B
- 10.14x
- ROE
- -323.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is AREC.LSE undervalued?
Graham numberThe Graham number of Arecor Therapeutics PLC cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Arecor Therapeutics PLC fundamental analysis
No fundamental analysis for Arecor Therapeutics PLC yet.
Arecor Therapeutics PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Arecor Therapeutics PLC
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics p…
Full company profileArecor Therapeutics PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Arecor Therapeutics PLC annual financial statements
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 1.35M | 1.89M | 1.70M | 1.16M | 2.40M | 4.57M | 5.05M | 1.71M | 776K |
| Gross Profit | 1.35M | 1.89M | 1.70M | 1.16M | 2.40M | 4.57M | 1.54M | 1.05M | 148K |
| Operating Income | -1.40M | -2.69M | -3.43M | -5.98M | -11.7M | -9.18M | -10.7M | -4.67M | -13.3M |
| EBITDA | -1.22M | -2.54M | -3.26M | -6.27M | -10.1M | -8.39M | -10.2M | -4.45M | -12.9M |
| Net Income | -1.12M | -2.19M | -2.75M | -6.17M | -9.26M | -8.55M | -10.2M | 664K | -11.9M |
| EPS | -0.04 | -0.08 | -0.10 | -0.27 | -0.32 | -0.28 | -0.31 | 0.02 | -0.32 |
| Balance Sheet | |||||||||
| Total Assets | 2.07M | 4.31M | 4.28M | 20.9M | 21.8M | 15.4M | 8.72M | 8.10M | 4.65M |
| Total Liabilities | 1.40M | 1.10M | 3.51M | 2.37M | 4.31M | 5.85M | 3.37M | 1.65M | 966K |
| Shareholders' Equity | 670K | 3.21M | 774K | 18.5M | 17.5M | 9.53M | 5.35M | 6.45M | 3.68M |
| Cash & Short-term Investments | 705K | 3.07M | 2.90M | 18.3M | 12.8M | 6.75M | 3.26M | 6.13M | 3.16M |
| Total Debt | 660K | 158K | 2.00M | 231K | 288K | 338K | 232K | 98.0K | 57.0K |
| Cash Flow | |||||||||
| Operating Cash Flow | -493K | -459K | -1.86M | -5.45M | -10.8M | -5.84M | -9.16M | -2.29M | -13.2M |
| Capital Expenditure | 12.9K | 32.3K | 52.3K | 69.0K | 345K | 151K | 23.0K | 99.0K | 100K |
| Free Cash Flow | -505K | -491K | -1.91M | -5.52M | -11.1M | -5.99M | -9.18M | -2.39M | -13.3M |
| Ratios | |||||||||
| ROE | -167.0% | -68.3% | -355.7% | -33.3% | -53.1% | -89.8% | -191.4% | 10.3% | -323.8% |
| ROA | -54.2% | -50.9% | -64.3% | -29.5% | -42.5% | -55.6% | -117.4% | 8.2% | -256.5% |
| Net Profit Margin | -82.9% | -115.8% | -162.1% | -532.7% | -385.4% | -187.1% | -202.6% | 38.7% | -1,537.1% |
| Debt to Equity | 0.98x | 0.05x | 2.58x | 0.01x | 0.02x | 0.04x | 0.04x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Arecor Therapeutics PLC dividends
Arecor Therapeutics PLC has not paid dividends in the last 8 fiscal years.
Who owns Arecor Therapeutics PLC
- Insiders 28.46%
- Institutions 41.93%
- Public & others 29.61%
- Shares outstanding 45.3M
- Free float 23.3M
Arecor Therapeutics PLC company profile
- Company name
- Arecor Therapeutics PLC
- Ticker
- AREC.LSE
- ISIN
- GB00BMWLM973
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Fiscal year end
- December
- Address
- Chesterford Research Park, Little Chesterford, United Kingdom, CB10 1XL
- Phone
- 44 1223 426 060
- Website
- arecor.com
About Arecor Therapeutics PLC
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
Arecor Therapeutics PLC management
4- Dr. Sarah Jennifer Howell Ph.D.CEO & Executive Director · born 1975
- Mr. David J. EllamCFO & Executive Director · born 1964
- Dr. Jan Jezek Ph.D.Chief Scientific Officer
- Mr. David GerringChief Development Officer